Merck Frosst files new drug application (NDA) for blood clot imaging agent:
This article was originally published in Clinica
Executive Summary
Merck Frosst has filed a Canadian NDA for a thrombus imaging agent. The agent is based on a genetically engineered human antibody to fibrin developed by US-based BioTechnology General.